Association Between Frailty and Short‐Term Treatment‐Related Adverse Events in Patients With Overactive Bladder
LUTS: Lower Urinary Tract Symptoms · 2026-05 · 18 (3)
DOI: 10.1111/luts.70060 ↗Kurz gefasst
Fachartikel in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, online erschienen am 09.04.2026. Verfasst von Sohei Iwagami und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kishiwada Tokushukai Hospital, Kishiwada-city, Japan. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Frailty, Cholinergic Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Objectives
To evaluate whether frailty at treatment initiation is associated with treatment‐related adverse events in patients with newly diagnosed overactive bladder (OAB).
Methods
This retrospective, single‐center cohort study included 122 patients who initiated pharmacotherapy for OAB between April 2024 and January 2026. Frailty was evaluated using the Frailty Screening Index and classified as robust, prefrail, or frail. The primary outcome was treatment‐related adverse events within 3 months, and independent predictors were identified using multivariable logistic regression. Longitudinal changes in OAB symptoms were examined using linear mixed‐effects models.
Results
During follow‐up, adverse events occurred in 52 patients (42.6%), rising with frailty (4.7%, 40.0%, and 57.3% in robust, prefrail, and frail groups, respectively; p < 0.01 for trend). In multivariable analysis, frailty (odds ratio [OR] 2.97 per status increase, 95% confidence interval [CI] 1.45–6.52; p < 0.01), anticholinergic use (OR 7.96, 95% CI 2.94–24.46; p < 0.01), and baseline post‐void residual volume (OR 1.22 per 10 mL increase, 95% CI 1.01–1.34; p = 0.02) were independently associated with adverse events; chronological age was not. Symptom improvement over time did not differ significantly by frailty status.
Conclusions
Frailty, rather than chronological age, was associated with short‐term treatment‐related adverse events among patients starting pharmacotherapy for OAB. Frailty assessment may help identify patients at higher risk of adverse events and support individualized, safety‐conscious treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kishiwada Tokushukai Hospital, Kishiwada-city, Japan.
ORCID-Profile: Sohei Iwagami, Hiraku Yamamoto
Zitieren
APA
Iwagami, S., Yamamoto, H., Miyai, H., & Nishihata, M. (2026). Association Between Frailty and Short‐Term Treatment‐Related Adverse Events in Patients With Overactive Bladder. LUTS: Lower Urinary Tract Symptoms, 18(3). https://doi.org/10.1111/luts.70060
Vancouver
Iwagami S, Yamamoto H, Miyai H, Nishihata M. Association Between Frailty and Short‐Term Treatment‐Related Adverse Events in Patients With Overactive Bladder. LUTS: Lower Urinary Tract Symptoms. 2026;18(3). doi:10.1111/luts.70060
BibTeX
@article{Iwagami2026,
author = {Iwagami, Sohei and Yamamoto, Hiraku and Miyai, Haruka and Nishihata, Masaya},
title = {Association Between Frailty and Short‐Term Treatment‐Related Adverse Events in Patients With Overactive Bladder},
journal = {LUTS: Lower Urinary Tract Symptoms},
year = {2026},
volume = {18},
number = {3},
doi = {10.1111/luts.70060}
}
EUVIMED